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Objective. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an autoimmune disease (AID) charac-
terised by necrotising intravascular inflammation. Growing evidence suggests that immune system triggers altered lipid metab-
olism in AIDs. We investigated whether changes in lipid profile correlate with severity of disease in AAV. Methods. Seven lipid 
profiles were evaluated utilizing frozen serum samples from 67 patients registered in the Severance Hospital ANCA-associated 
VasculitidEs cohort by a chemistry autoanalyzer. The Birmingham Vasculitis Activity Score (BVAS) version 3 was used to meas-
ure patient’s assessment of global disease activity. The relationship between the BVAS with continuous variables was calculated 
by Pearson’s correlation analysis. Results. Thirty-five (52.2%), 19 (28.4%), and 13 (19.4%) patients were diagnosed with micro-
scopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis, respectively. Patients’ 
mean age was 60.0 years, and 22 (32.8%) were male. Among the lipid profiles investigated, total cholesterol, high-density lip-
oprotein, and low-density lipoprotein, and apolipoprotein A1 and B were significantly associated with BVAS; apolipoprotein 
A1 showed the highest correlation with BVAS (r=−0.521, p＜0.001), remaining consistent even in patients with new-onset 
disease (r=−0.430, p=0.012). Apolipoprotein A1 had the highest association with the renal manifestation score among the 
clinical scores comprising BVAS (r=−0.457, p＜0.001). Conclusion. Decreased lipid levels, especially apolipoprotein A1, are 
relevant to increased AAV disease activity, and differ according to organ involvement. Measuring lipid profiles could have clin-
ical implications regarding the assessment of global disease activity and organ involvement patterns. (J Rheum Dis 2020;27:261
-269)
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INTRODUCTION
Anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV) is a rare autoimmune disease (AID) in-
volving the small vessels and mainly affecting older pa-
tients [1]. Three distinct groups of diseases―micro-
scopic polyangiitis (MPA), granulomatosis with poly-
angiitis (GPA), and eosinophilic polyangiitis (EGPA)―
comprise AAV, which is typically associated with necrot-
ising intravascular inflammation [2,3]. In AAV, multiple 
aetiologies, including environmental factors, genetics, 
and infection, are proposed to contribute to the patho-
genesis; however, growing evidence indicates that im-
mune dysregulation is crucial in provoking and perpetu-
ating the inflammatory response [4]. Interestingly, it has 
been identified that the trigger of innate and adaptive im-
munity could cause a shift in metabolic activity [5]. 
Meanwhile, even though remarkable advances have re-
cently been made in the understanding of AAV, the clin-
ical and laboratory aspects associated with inflammation 
remain to be better investigated.
Compelling evidence now indicates that patients with 
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AIDs show altered lipid metabolism, which could differ 
based on the underlying disease [6]. In rheumatoid ar-
thritis (RA), it is described that patients with active dis-
ease exhibit a “lipid paradox”, in which reduced total, 
high-density lipoprotein (HDL), and low-density lip-
oprotein (LDL) cholesterol are present in proportion to 
the degree of inflammation [7]. Similarly, it has been 
shown that patients with systemic lupus erythematosus 
(SLE) present with decreased total and HDL cholesterol, 
whereas triglyceride, total, and LDL cholesterol levels are 
elevated at the time of diagnosis [8]. Of note, it was dem-
onstrated that low HDL cholesterol was associated with 
higher disease activity in SLE, whereas alterations of tri-
glyceride levels indicated changes in disease activity, em-
phasising that lipid profiles could be affected by in-
flammation, and could be markers of disease severity in 
AIDs. However, owing to the rarity of the disease, the lip-
id profiles in patients with AAV and their relationship 
with disease activity has not yet been well determined. 
Therefore, the objective of this study was to investigate 




We included 67 AAV patients who were registered in the 
Severance Hospital ANCA-associated VasculitidEs (SHAVE) 
cohort. Patients diagnosed with AAV as defined by the 
2007 European Medicine Agency algorithms for AAV and 
polyarteritis nodosa, as well as the 2012 International 
Chapel Hill Consensus Conference Nomenclature of 
Vasculitides at the Division of Rheumatology in Severance 
Hospital, are enrolled in the SHAVE cohort [9,10]. All of 
the included patients were not using cholesterol-low-
ering drugs and had their serum samples collected on 
fasting. In addition, patients with malignancies, chronic 
infections such as hepatitis B or C virus, or other auto-
immune diseases that could mimic AAV were excluded. 
Patients registered in the SHAVE cohort are subject to 
routine assessment of clinical and laboratory data at an 
interval of three to six months, undergo simultaneous 
blood sampling, and have their sera isolated and stored. 
Written informed consent was obtained from the patients 
prior to blood sampling, and the Institutional Review 
Board of Severance Hospital (4-2016-0901) approved 
this study.
Clinical and laboratory data collection and lipid 
profile assessment
Clinical data collected at the date of blood sampling 
were as follows; AAV subtypes, demographic data of age, 
sex, new-onset disease (disease duration less than one 
month), the Birmingham Vasculitis Activity Score (BVAS) 
version 3, and presence of comorbid hypertension, dia-
betes mellitus, or dyslipidemia [11,12]. Both incident 
and prevalent cases of AAV were enrolled. In addition, the 
following data were gathered from patient’s electronic 
medical records: 1) information on clinical manifes-
tations and the respective clinical scores based on BVAS, 
and 2) current prescription of immunosuppressive agents 
to treat AAV. Laboratory data consisted of ANCA seros-
tatus, white blood cell and platelet counts, along with cre-
atinine, erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP), complement (C)3, and C4 levels.
The frozen serum samples obtained from patients were 
thawed and analysed for seven different lipid profile tests, 
namely total cholesterol, triglyceride, HDL and LDL cho-
lesterol, and lipoprotein (a), and apolipoproteins A1 and 
B. The determination of total cholesterol, triglyceride, 
HDL, and LDL cholesterol level was done by using the 
Hitachi 7600 automated chemistry analyser (Hitachi Co., 
Tokyo, Japan), while lipoprotein (a), and apolipoproteins 
A1 and B levels were estimated using the Cobas c702 
chemistry autoanalyser (Hitachi Co.).
Statistical analyses
Statistical analyses were performed using MedCalc ver-
sion 19.3.1 (MedCalc Software bvba, Ostend, Belgium). 
Continuous and categorical variables were represented as 
mean±standard deviation and number (%). Patients 
were divided into the high disease activity group (BVAS 
≥12) and the low disease activity group (BVAS ＜12), as 
described in our previous study [13]. Differences be-
tween continuous variables were compared by Student’s 
t-test for two groups and by analysis of variance for three 
groups. Correlation coefficient and 95% confidence inter-
vals (CI) between continuous variables were estimated 
using Pearson’s correlation analysis. In all statistical anal-
yses, a two-tailed p-value ＜0.05 was considered significant.
RESULTS
Clinical and laboratory characteristics of patients 
The patients’ clinical and laboratory characteristics are 
shown in Table 1. Thirty-five (52.2%), 19 (28.4%), and 13 
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Table 1. Baseline characteristics of patients with AAV
Variables Total (n=67)
High disease activity 
(n=25)




   MPA 35 (52.2) 15 (60.0) 20 (47.6)
   GPA 19 (28.4)   7 (28.0) 12 (28.6)
   EGPA 13 (19.4)   3 (12.0) 10 (23.8)
Demographic data
   Age (yr)   60.0±14.3   59.5±16.8   60.2±12.9 0.850
   Male sex 22 (32.8) 10 (40.0) 12 (28.6) 0.339
   Body mass index (kg/m2)  21.9 ±3.4   21.3±3.1   22.2±3.6 0.300
   New-onset disease* 33 (49.3) 20 (80.0) 13 (31.0) ＜0.001
   Disease duration (mo)   17.2±31.0     5.6±21.3   24.1±33.9 0.008
   BVAS     9.8±6.8   17.5±3.9     5.2±2.8 ＜0.001
ANCA serostatus 
   MPO-ANCA (or P-ANCA) positivity 39 (58.2) 18 (72.0) 21 (50.0) 0.080
   PR3-ANCA (or C-ANCA) positivity   6 (9.0)   3 (12.0)   3 (7.1) 0.664
   ANCA negativity 22 (32.8)   4 (16.0) 18 (42.9) 0.032
Comorbidities 
   Hypertension 13 (19.4)   6 (24.0)   7 (16.7) 0.466
   Diabetes mellitus 12 (17.9)   6 (24.0)   6 (14.3) 0.320
   Dyslipidemia 27 (40.3) 13 (52.0) 14 (33.3) 0.135
Laboratory results 
   White blood cell count (/mm3)     8.9±4.4   10.4±5.5     8.0±3.4 0.033
   Platelet count (×1,000/mm3) 308.5±145.9 349.7±199.0 284.1±97.1 0.075
   Creatinine (mg/dL)     1.9±1.9     2.9±2.2     1.3±1.3 ＜0.001
   ESR (mm/h)   46.2±33.6   59.1±39.6   38.6±27.3 0.015
   CRP (mg/L)   20.6±41.7   35.2±50.4   11.8±33.3 0.025
   C3 (mg/dL) 112.0±25.0 103.9±26.7 116.9±23.0 0.039
   C4 (mg/dL)   24.5±8.9   23.0±10.1   25.4±8.1 0.296
Lipid profiles
   Total cholesterol (mg/dL) 192.4±49.4 161.8±40.1 210.7±45.6 ＜0.001
   Triglyceride (mg/dL) 132.2±67.1 133.8±60.8 131.3±71.3 0.880
   HDL cholesterol (mg/dL)   56.1±19.4   45.4±18.4   62.4±17.3 ＜0.001
   LDL cholesterol (mg/dL) 110.2±34.8   89.3±28.4 122.6±32.4 ＜0.001
   Lipoprotein (a) (mg/dL)   31.7±30.1   36.6±37.1   28.8±25.1 0.310
   Apolipoprotein A1 (mg/dL) 150.3±37.6 126.4±34.6 164.5±32.0 ＜0.001
   Apolipoprotein B (mg/dL) 100.3±27.6   89.2±21.7 107.0±28.8 0.010
Values are presented as number (%) or mean±standard deviation. AAV: anti-neutrophil cytoplasmic antibody-associated 
vasculitis, MPA: microscopic polyangiitis, GPA: granulomatosis with polyangiitis, EGPA: eosinophilic granulomatosis with 
polyangiitis, BVAS: Birmingham Vasculitis Activity Score, ANCA: anti-neutrophil cytoplasmic antibody, MPO: myeloperoxidase, 
P: perinuclear, PR3: proteinase 3, C: cytoplasmic, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, C3: complement 
3, C4: complement 4, HDL: high-density lipoprotein, LDL: low-density lipoprotein. *Patients who were diagnosed with AAV 
within one month were defined as having new-onset disease.
(19.4%) patients were diagnosed with MPA, GPA, and 
EGPA, respectively. The mean age of patients was 60.0 
years, and 22 (32.8%) of the patients were male. When 
the patients were divided into high disease and low dis-
ease activity group, patients with high disease activity had 
greater proportion of those with new-onset disease 
(80.0% vs. 31.0%, p＜0.001) and the BVAS was higher 
compared to those with low disease activity. Regarding 
ANCA serostatus and laboratory results, ANCA neg-
ativity was found more frequently in those with low dis-
ease activity, and the mean levels of white blood cells, cre-
atinine, ESR, and CRP were significantly higher in the 
high disease activity group, whereas the C3 level was low-
er in the low disease activity group. Moreover, when the 
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Table 2. Clinical manifestation and immunosuppressive agent usage in patients with high and low disease activity
Variables High disease activity (n=25) Low disease activity (n=42) p-value
Clinical manifestations 
   General 14 (56.0) 11 (26.2) 0.015
   Cutaneous 3 (12.0) 3 (7.1) 0.664
   Mucous membranes/eyes 3 (12.0) 2 (4.8) 0.354
   Ear Nose Throat 10 (40.0) 17 (40.5) 0.970
   Pulmonary 19 (76.0) 24 (57.1) 0.122
   Cardiovascular 3 (12.0) 1 (2.4) 0.143
   Gastrointestinal 0 (0.0) 0 (0.0) NA
   Renal 21 (84.0) 14 (33.3) ＜0.001
   Nervous 5 (20.0) 11 (26.2) 0.568
Administration of immunosuppressive agent 
   Glucocorticoids 15 (60.0) 31 (73.8) 0.242
   Glucocorticoid dosage (mg/d)* 99.9±269.3 12.9±20.5 0.120
   Cyclophosphamide 5 (20.0) 11 (26.2) 0.568
   Rituximab 1 (4.0) 0 (0.0) 0.373
   Azathioprine 2 (8.0) 11 (26.2) 0.109
   Methotrexate 1 (4.0) 0 (0.0) 0.373
Values are presented as number (%) or mean±standard deviation. NA: not available. *The dosage of glucocorticoids was 
calculated into an equivalent dose of prednisolone.
lipid profiles were compared between the two groups, pa-
tients with high disease activity had significantly lower 
levels of total, HDL and LDL cholesterol, and apolipopro-
teins A1 and B. Patients with high disease activity more 
often presented with general and renal manifestation 
than did with low disease activity, but no differences in 
the administration of immunosuppressive agents were 
found between the groups (Table 2).
Relationship between BVAS, laboratory data, and 
lipid profiles
Laboratory data of ESR and CRP, and the lipid profiles 
were selected to evaluate association with BVAS. The val-
ues of total cholesterol, HDL and LDL cholesterol, apoli-
poproteins A1 and B, ESR, and CRP were significantly as-
sociated with BVAS (Figure 1). In contrast, in a subgroup 
analysis of patients with new-onset disease, only HDL 
cholesterol, lipoprotein(a), and apolipoprotein A1 were 
significantly associated with BVAS (Figure 2). In both 
analyses, apolipoprotein A1 was identified to have the 
highest absolute value of correlation coefficient with 
BVAS (r=−0.521, 95% CI −0.677 to −0.321, p＜0.001 
in total patients, r=−0.430, 95% CI −0.674 to −0.102, 
p=0.012 in patients with new-onset disease) (Figures 1 
and 2).
To further investigate the correlation between lipid pro-
files and the predisposition for organ-specific involve-
ment, we assessed the association of lipid profiles and 
clinical scores comprising BVAS. The relationship be-
tween the general manifestation score was most closely 
associated with CRP, whereas the mucous membranes/ 
eyes scores were only significantly associated with trigly-
ceride and ESR levels. In addition, pulmonary scores were 
correlated with total cholesterol and apolipoprotein A1, 
while apolipoprotein A1 had the highest absolute correla-
tion coefficient values with the renal manifestation score 
(r=−0.457, p＜0.001) (Table 3).
Lipid profiles according to clinical diagnosis and 
ANCA serostatus
We compared the lipid profiles of the patients according 
to the clinical diagnosis and ANCA serostatus. However, 
there were no significant differences in lipid profiles ac-
cording to the clinical diagnoses of MPA, GPA, and EGPA 
(Supplementary Figure 1). Similarly, the level of lipid pro-
files investigated appeared comparable even when divid-
ing the patients into myeloperoxidase (MPO)-ANCA, 
proteinase 3 (PR3)-ANCA, and ANCA-negative groups 
(Supplementary Figure 2).
DISCUSSION
Although research concerning lipid profiles and its clin-
ical significance in patients with AAV is scarce, a recent 
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Figure 1. Association between laboratory data and BVAS in AAV. The correlation between BVAS and laboratory data were as-
sessed in total patients (n=67). BVAS: Birmingham Vasculitis Activity Score, AAV: anti-neutrophil cytoplasmic antibody-associated
vasculitis, HDL: high-density lipoprotein, LDL: low-density lipoprotein, ESR: erythrocyte sedimentation rate, CRP: C-reactive 
protein.
publication by Wallace and colleagues [14] analysed lipid 
levels in patients’ sera from the Rituximab for ANCA- 
Associated Vasculitis (RAVE) trial. This study revealed 
that lipid levels of total and LDL cholesterol and of apoli-
poproteins A1 and B increase after treatment in patients 
with newly diagnosed AAV, implying that the decrease of 
lipid profiles is relevant to a higher inflammatory burden 
in AAV. These findings were reproduced in our study, as 
BVAS, which estimates patients’ assessment of global dis-
ease activity in AAV, was inversely correlated with total 
and LDL cholesterol and apolipoprotein A1 and B levels. 
This confirmed that escalated inflammation directly con-
tributes to the decrease of lipids. However, in our study, 
the HDL cholesterol level was also associated with dis-
ease activity in AAV. Of special interest, we demonstrated 
that only HDL cholesterol and apolipoprotein A1 were 
significantly associated with BVAS, even in patients with 
new-onset disease. Moreover, the absolute value of the 
correlation coefficient between BVAS and apolipoprotein 
A1 was the highest among the lipid profiles and acute 
phase reactants, indicating that apolipoprotein A1 could 
be a surrogate marker of disease activity in AAV.
It is unclear why apolipoprotein A1 is most relevant to 
disease severity in AAV within the lipid profiles 
investigated. However, this could be partly attributed to 
the anti-inflammatory properties of HDL cholesterol, and 
due to apolipoprotein A1’s critical role in modulating the 
function of HDL cholesterol. HDL cholesterol is tradi-
tionally considered “good” cholesterol because it re-
moves cholesterol from local tissues; it also transports ex-
cess cholesterol to the liver, in a process known as reverse 
cholesterol transport, thereby exerting protective effects 
in the development of atherosclerosis and cardiovascular 
diseases [15,16]. In contrast, HDL cholesterol has also 
been acknowledged to have anti-inflammatory character-
istics, as it suppresses antigen presenting cells and T-cell 
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Figure 2. Association between laboratory data and BVAS in new-onset AAV. The correlation between BVAS and laboratory data
were assessed in patients with new-onset disease (n=33). BVAS: Birmingham Vasculitis Activity Score, AAV: anti-neutrophil cyto-
plasmic antibody-associated vasculitis, HDL: high-density lipoprotein, LDL: low-density lipoprotein, ESR: erythrocyte sed-
imentation rate, CRP: C-reactive protein.
Table 3. Association between lipid profiles, acute phase reactants, and clinical scores comprising BVAS
Laboratory data
Clinical manifestations
General Mucous membranes/eyes Pulmonary Renal
Total cholesterol −0.408 (＜0.001) −0.085 (0.496) −0.264 (0.031) −0.304 (0.012)
Triglyceride 0.020 (0.873) 0.390 (0.001) −0.056 (0.652) 0.033 (0.794)
HDL cholesterol −0.408 (＜0.001) −0.217 (0.078) −0.203 (0.099) −0.336 (0.005)
LDL cholesterol −0.364 (0.003) −0.100 (0.423) −0.225 (0.067) −0.314 (0.010)
Lipoprotein (a) −0.057 (0.647) −0.009 (0.942) −0.052 (0.677) 0.023 (0.853)
Apolipoprotein A1 −0.450 (＜0.001) −0.155 (0.210) −0.258 (0.035) −0.457 (＜0.001)
Apolipoprotein B −0.234 (0.057) −0.001 (0.990) −0.174 (0.159) −0.196 (0.113)
ESR 0.345 (0.004) 0.301 (0.013) 0.084 (0.500) 0.320 (0.008)
CRP 0.488 (＜0.001) 0.229 (0.062) 0.217 (0.077) 0.282 (0.021)
The values indicate correlation coefficients; those in parentheses indicate p-values. BVAS: Birmingham Vasculitis Activity Score,
HDL: high-density lipoprotein, LDL: low-density lipoprotein, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein.
activation [17,18]. In line with these findings, a previous 
study indicated that infusion of HDL cholesterol could al-
leviate arthritis in an experimental model of RA [19]. 
Meanwhile, apolipoprotein A1 is a major protein that 
constitutes nearly 70% of proteins in HDL, and facilitates 
the transfer of cholesterol to HDL from tissues, and the 
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transport of HDL cholesterol within the circulation to the 
liver [20]. Given that apolipoprotein A1 is essential to the 
function of HDL cholesterol, the decrease of apolipopro-
tein A1 may be most significantly related to higher dis-
ease activity in AIDs, particularly AAV. Interestingly, a 
previous study has also shown that apolipoprotein A1 
and HDL cholesterol levels decrease in the sera of pa-
tients with inflammatory arthritis compared to controls, 
which supports our hypothesis [21]. Moreover, it was 
demonstrated in the same study that apolipoprotein A1 is 
decreased in the blood and increased in the inflamed 
joints in RA, indicating that the decrease of apolipopro-
tein A1 in the circulation could be closely linked to the in-
flammatory process. 
Similarly, when we analysed the association between 
lipid profiles, acute phase reactants, and the clinical scores 
comprising BVAS, it was demonstrated that apolipopro-
tein A1 was significantly correlated with general, pulmo-
nary, and renal manifestation scores. Notably, apolipo-
protein A1 had the highest correlation with the renal 
manifestation score among the laboratory variables 
included. In addition, even though CRP, a representative 
acute phase reactant used to assess the degree of in-
flammation, had a higher correlation with general mani-
festation scores than did apolipoprotein A1, apolipopro-
tein A1 better correlated with the renal manifestation 
scores than did CRP. Taken together, it is suggested that 
the differential expression of lipid profiles could be help-
ful in predicting organ involvement patterns in AAV. 
While the three representative diseases of MPA, GPA, 
and EGPA are traditionally known to comprise a group of 
AAV, it is increasingly understood that a distinct feature 
could be present according to the ANCA serostatus and 
the diagnosis [22,23]. In addition, it was described that 
total and LDL cholesterol and apolipoprotein B levels are 
significantly elevated following treatment in PR3-ANCA- 
positive patients, but not in MPO-ANCA positive pa-
tients [14]. However, our observations revealed no differ-
ences in lipid profiles regarding diagnosis or ANCA 
serostatus. Although the difference in study design could 
have affected the discordant result, this discrepancy could 
be also accounted for by the fact that PR3-ANCA is de-
tected more frequently than is MPO-ANCA in AAV pa-
tients in the Western world, and is associated with higher 
disease relapse [24-26]. In contrast, MPO-ANCA-pos-
itive AAV is more common than is PR3-ANCA positive 
AAV in Asia, and its presence is associated with higher 
disease activity in Korean patients [24,27]. Therefore, in-
creased inflammatory burdens, rather than disease sub-
types or ANCA types, may be an important factor influ-
encing lipid profiles in patients with AAV.
Besides disease activity, medications treating dyslipidae-
mia, as well as glucocorticoids and immunosuppressive 
agents, could also affect patients’ lipid profiles [28,29]. 
Accordingly, in the study design, we only included pa-
tients with AAV not taking lipid-lowering agents, and the 
immunosuppressants that were being administered were 
also compared between patients with high and low dis-
ease activity. However, our findings indicate that the use 
of medications was comparable between the two groups, 
implying that immunosuppressant use did not sig-
nificantly impact the lipid profiles of our study population. 
Several inherent limitations are present in this study. 
First, the number of patients enrolled in this study was 
relatively small, which could have affected data inter-
pretation. Furthermore, as we defined the patients into 
high disease activity and low disease activity group ac-
cording to the BVAS cut-off of 12, this could have influ-
enced in the study results. Second, as this study was a 
cross-sectional study, we were not able to evaluate the 
changes of lipid profiles according to the alterations of 
disease activity. In addition, due to the lack of a control 
group, a direct comparison of lipid profiles could not be 
made with that of the normal population. Third, data of 
lifestyle habits such as alcohol ingestion and smoking, 
which could impact in the lipid profiles, was not collected 
in this study. Fourth, the present study did not provide 
the mechanism leading to dysregulated lipid profiles. 
Hence, further exploration is necessary to understand the 
pathways that lead to aberrant lipid levels in AAV. Fifth, it 
is unclear whether the decrease in lipid profiles that were 
observed in this study is a general phenomenon in chron-
ic inflammatory diseases or is a specific finding for AAV, 
and should be addressed through future studies.
CONCLUSION
In summary, we confirmed that lipid profiles are altered 
in patients with AAV; among the lipid profiles inves-
tigated, the decrease in apolipoprotein A1 level is most 
relevant to increased disease activity. Moreover, it was 
found that the expression of lipid profiles differed accord-
ing to patterns of organ involvement. These results sug-
gest that measuring lipid profiles could have clinical im-
plications regarding the assessment of global disease ac-
tivity and organ involvement in AAV. 
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